NOT FDA-APPROVED

GLOW Blend

A three-peptide skin-and-aesthetics blend: GHK-Cu + BPC-157 + TB-500. The most popular peptide stack for skin tone, collagen, and post-procedure recovery research, combining one peptide with strong topical evidence with two studied for tissue repair.

The 30-second read

The GLOW blend combines GHK-Cu (the copper peptide with decades of cosmetic-science research), BPC-157, and TB-500. The pitch: GHK-Cu stimulates collagen and skin-firmness markers, BPC-157 promotes blood-vessel formation and growth-factor signaling, TB-500 supports cell migration. Together, in theory, you cover most of the skin-repair cascade. The reality: there are zero published human studies of this specific three-peptide combination. Each component individually has its own evidence base, strongest for topical GHK-Cu, thinnest for the systemic-injection use case the blend is usually delivered as. Not FDA-approved. Two of the three components (BPC-157, TB-500) are on the FDA's Category 2 list.

Why this blend is on people's radar

The GLOW name caught on because the components have complementary stories on paper. GHK-Cu has a 50-year cosmetic-research track record, it's the peptide most credibly associated with collagen synthesis and skin tone improvements. BPC-157 and TB-500 form the Wolverine recovery stack, with broader tissue-repair narratives behind them. Combining all three was a natural extension: take the most-evidenced skin peptide and add the most-discussed tissue-repair peptides, all in one injection.

In research-peptide circles, GLOW shows up most often in three contexts. First, post-procedure recovery, patients who've had a laser treatment, microneedling session, or cosmetic procedure use GLOW to (theoretically) speed healing and reduce downtime. Second, general anti-aging skin protocols, especially in adults watching collagen loss and skin tone changes. Third, hair and follicle support. GHK-Cu has a smaller body of hair-follicle research that sometimes gets cited in the blend context.

The honest framing has to acknowledge what the blend isn't: clinically validated. There are no human trials of this specific three-peptide combination. The marketing around GLOW often borrows credibility from GHK-Cu's cosmetic-science history without acknowledging that the GHK-Cu evidence is mostly topical, while the blend is typically delivered as an injection. Different routes, different evidence base.

What people are usually trying to do with it

People exploring the GLOW blend are usually focused on:

  • Improving skin tone, firmness, and texture over weeks of use
  • Recovering from a cosmetic procedure (laser, microneedling, peels) faster and with better outcomes
  • Supporting hair follicle health and visible thickness
  • Reducing the appearance of fine lines, scars, or hyperpigmentation
  • Combining skin support with general tissue-repair effects in one stack

What the science actually shows

Plain-English summary, with the most important caveat first:

No human trials of the blend

Zero published human clinical trials of the GHK-Cu + BPC-157 + TB-500 combination. Anything anyone claims about the blend's effectiveness rests on extrapolation from individual-component research and on anecdote.

GHK-Cu individual research (the strongest part)

50+ years of cosmetic-science research, multiple human studies on topical use, consistent reports of collagen synthesis and skin firmness improvements. The strongest part of the blend's evidence base, and importantly, mostly for topical use, not injection. Full GHK-Cu explainer →

BPC-157 individual research

Roughly 1,000+ preclinical publications and ~3 small human pilot studies. Animal evidence supports tissue-repair effects in tendon, gut, and muscle models. Human evidence is much thinner. Full BPC-157 explainer →

TB-500 individual research

Decades of Thymosin Beta-4 preclinical work on cell migration and wound healing. The synthetic 17-amino-acid TB-500 fragment has thinner clinical evidence specifically. Full TB-500 explainer →

Mechanistic complementarity (theoretical)

The case for combining these three is that GHK-Cu drives collagen and elastin in dermal fibroblasts, BPC-157 supports angiogenesis and growth-factor expression, and TB-500 facilitates cell migration. Three different parts of the skin-repair cascade. Plausible biology. Not proven synergy in humans.

What the blend has not been shown to do

Reliably improve any specific skin or aesthetic outcome in a controlled human trial. Outperform topical GHK-Cu alone for skin (which has more evidence than any of the injectable options). Replace established cosmetic procedures (lasers, microneedling, retinoids), those have stronger clinical evidence than any peptide blend.

The honest read

What's solid:

Each component has its own real evidence base. GHK-Cu in particular has decades of credible cosmetic-science research. The mechanistic case for combining peptides that act on different parts of skin and tissue repair is biologically reasonable.

What's still unproven:

Effectively everything about the blend specifically. No human trials of the combination exist. The route-of-administration question is real, most GHK-Cu evidence is topical, while the blend is typically delivered as an injection. Whether injectable BPC-157 and TB-500 add anything to topical GHK-Cu's known effects in human skin isn't established.

What's hyped beyond the evidence:

Treating GLOW as a clinically established anti-aging or skin-rejuvenation stack. The cosmetic-procedure recovery use case is supported by anecdote, not by trials. Claims that the blend dramatically outperforms topical retinoids, properly-administered GHK-Cu serums, or established procedures aren't supported by any published comparison.

Things to know if you're looking into it

  • How it's typically used: as a pre-mixed subcutaneous injection containing all three peptides. Some research-community protocols layer topical GHK-Cu on top of injectable BPC-157 + TB-500 instead.
  • Component status: GHK-Cu is widely available as a cosmetic ingredient (much lower regulatory bar than drug approval) and as a research peptide. BPC-157 and TB-500 are both on the FDA's Category 2 list (since September 2023), making compounding-pharmacy access legally restricted.
  • Topical vs. injectable distinction matters: the strongest GHK-Cu evidence is for topical use. The blend is typically injected. People interested in the GHK-Cu story specifically may want to consider whether topical use makes more sense for them than systemic injection.
  • Athlete bans: BPC-157 and TB-500 are on the WADA banned list. Competitive athletes will test positive even from the blend.
  • Pairs with sun protection and skin care: the most-evidenced anti-aging interventions remain sun protection, retinoids, and skin care basics. GLOW is at most an addition, not a replacement.
  • Healthcare provider involvement: recommended for any decision about use, especially post-procedure use where infection or healing complications need to be managed clinically.
  • Specific dosing protocols and component breakdowns: all in the "Want to go deeper?" section below.

Reconstitution & dose calculator

3-peptide blend (GHK-Cu : BPC-157 : TB-500 in a 5:1:1 ratio). Zero published human studies on this specific combination. Two of three components (BPC-157, TB-500) are on the FDA Category 2 list. None of the three is FDA-approved. The dose math below uses combined peptide mass — because the components are unequal, a 1500 mcg combined dose is roughly 1071 mcg GHK + 214 mcg BPC + 214 mcg TB (the calculator shows the live breakdown). Compounded blend quality varies. WADA bans BPC-157 and TB-500. This is an educational reference, not dosing guidance.
Suggested start
1000 mcg/inj
~714 GHK + 143 BPC + 143 TB
Common range
1500–2000 mcg/inj
Lands all three components in their per-component ranges
Max dose
3000 mcg/inj
~2143 GHK + 429 BPC + 429 TB — community ceiling
Cycle
6–8 wks on
Then 2–4 weeks off — copper accumulation matters
mL
Defaults to ~23 mg/mL combined (3 mL into a 70 mg vial) — standard reconstitution that fits comfortably in the vial. Common dose draws land in the 4–13 syringe-unit range. For larger draw volumes, reconstitute with 5 mL water (14 mg/mL) and the units roughly double.
mcg
Subcutaneous injection, typically once daily. Blend ratio is 5:1:1 — for every 7 mcg combined, 5 mcg is GHK-Cu, 1 mcg is BPC-157, 1 mcg is TB-500. So a 1500 mcg combined dose = ~1071 mcg GHK + ~214 mcg BPC + ~214 mcg TB. The unequal ratio means "combined dose" isn't a free-standing number — what matters is whether each component lands in its individual range.
Concentration
23.3 mg/mL
Per dose
0.064 mL
6.4 units on insulin syringe
Doses per vial
~46
~46 days (~6.6 weeks) of daily dosing

When to stay put vs. adjust

Stay put at 1500 mcg combined daily when skin tone, firmness, or post-procedure recovery is gradually improving — effects on collagen and tissue work on weeks-to-months timelines, not days. The GHK-Cu component drives the visible-skin effects; the BPC and TB components add general tissue support. Don't escalate just because results aren't dramatic in week one.

Consider stepping to 2000–2500 mcg combined only after at least four weeks at 1500 mcg with clear tolerability and limited progress on the issue you're tracking. Above 2000 mcg combined, you're putting the GHK-Cu component into its higher dose range; above 3000 mcg, you exit common protocols entirely.

Cycle off at the 6–8 week mark regardless of progress — specifically because of the GHK-Cu copper component. Copper is a metal that can accumulate in tissues, and the off-period gives the body a clearance window. This isn't tradition for tradition's sake; it's the conservative move for any copper-containing peptide protocol.

The frequency-mismatch caveat from Wolverine partly applies here. BPC-157 is normally daily; TB-500 is normally 1–2× weekly because of half-life differences; GHK-Cu is normally 2–3× weekly. A pre-mixed daily-dosing GLOW blend forces all three onto the same schedule. Some users prefer to dose GLOW 3–4× weekly instead to better match the slower components' natural cadence; others stay daily and accept the mismatch. There's no clinical data showing which approach is better. If you want individual-component dosing, use the three peptides as separate injections rather than a blend.

Pair with sun protection and skin care basics, not in place of them. The most-evidenced anti-aging interventions remain sunscreen, retinoids, and the rest of the skin-care fundamentals. GLOW is at most an addition. People who use the blend instead of the basics tend to be disappointed in the result.

Watch for injection-site reactions and skin changes around the injection site. Copper-containing peptides can cause local irritation; rotate injection sites and reduce frequency or dose if redness, itching, or unusual skin changes appear. People with Wilson's disease or other copper-metabolism disorders should avoid copper peptides entirely — that includes any blend containing GHK-Cu.

The honest read. Zero published human trials of this specific 3-peptide combination. The mechanistic case — GHK-Cu for collagen, BPC and TB for tissue repair, all in one shot — is reasonable on paper, but reasonable-on-paper isn't evidence. The strongest individual-component evidence (GHK-Cu) is mostly for topical use, while the blend is delivered as injection. Different routes, different evidence base. Compounded blend quality varies meaningfully — actual peptide content can differ from the label.

For educational and research purposes only. This is not medical advice. None of the three components is FDA-approved as a drug; BPC-157 and TB-500 are on the FDA Category 2 list (Sept 2023). BPC-157 and TB-500 are on WADA and most pro/collegiate sports prohibited-substance lists. People with Wilson's disease or other copper-metabolism disorders should avoid this blend. Compounded blends operate outside FDA drug oversight. Consult a licensed healthcare provider before any health decision.

What people often ask

Is GLOW better than topical GHK-Cu serum?

No head-to-head trials. The strongest GHK-Cu evidence is for topical use, while the blend is typically injected. Adding BPC-157 and TB-500 may add benefit, may not. The most evidence-based GHK-Cu use case remains topical.

Will it help my skin tone or wrinkles?

The mechanism is plausible, the human evidence for the specific blend doesn't exist, and individual responses vary widely. Anecdotal reports range from meaningful improvements to no perceptible change.

Is it safe?

Each component has limited human safety data individually, and there's no safety data on the combination specifically. Reported side effects in research-community use are generally mild and uncommon. Long-term safety isn't characterized.

Can I use it after a cosmetic procedure?

Some clinics and research-community protocols use GLOW post-procedure for theoretical recovery support. Whether it actually speeds healing or improves outcomes versus standard post-procedure care isn't established. Talk to the clinician who did the procedure first.

What about hair regrowth?

GHK-Cu has a smaller body of hair-follicle research. The blend gets used in hair contexts but with even less specific evidence. For meaningful hair concerns, FDA-approved interventions (minoxidil, finasteride for those for whom it's appropriate) have more evidence.

Can copper accumulate from chronic use?

Theoretically yes, particularly with chronic high-dose injectable GHK-Cu use. People with copper-metabolism disorders (Wilson's disease) should avoid copper peptides. Long-term injectable use isn't well-characterized for cumulative copper effects.

Is it FDA-approved?

No. Not approved as a combined formulation. Two of the three components (BPC-157, TB-500) are on the FDA's Category 2 list as of September 2023.

FDA and regulatory status

Status as of May 5, 2026: The GLOW blend is not FDA-approved as a combined formulation. GHK-Cu is widely available as a cosmetic ingredient and not on the FDA Category 2 list. BPC-157 and TB-500 are both on the FDA's Category 2 list (since September 2023), making compounding-pharmacy access legally restricted for those components. The April 2026 FDA panel review of compounded peptides included BPC-157 and TB-500 in scope. Status updates land here when they happen.

Want to go deeper? Component breakdowns, mechanism complementarity, blend dosing considerations, side effects, and references. Click to expand.

The three components, briefly

GHK-Cu, the copper-peptide skin specialist

A copper-binding tripeptide with 50+ years of cosmetic-science research. Strongest evidence for topical use in skin firmness, collagen synthesis, and skin-tone improvements. Read the full GHK-Cu explainer →

BPC-157, angiogenesis and growth-factor signaling

A 15-amino-acid peptide derived from a protective protein in human gastric juice. Animal-model evidence for blood-vessel formation and tissue-repair effects. ~3 small human pilot studies; thousands of preclinical publications. Read the full BPC-157 explainer →

TB-500, cell migration

A 17-amino-acid synthetic fragment of Thymosin Beta-4. Animal-model evidence for cell migration during tissue repair. The cell-migration partner to BPC-157 in the Wolverine stack as well. Read the full TB-500 explainer →

Mechanism of the combination (theoretical)

The case for combining these three peptides rests on layered mechanism complementarity:

  • GHK-Cu: upregulates collagen and elastin synthesis in dermal fibroblasts, antioxidant effects via copper cofactor, modulation of skin-related gene expression.
  • BPC-157: promotes new blood-vessel formation, growth-factor expression (VEGF, EGF, FGF), nitric oxide pathway modulation.
  • TB-500: supports cell migration via actin sequestration, anti-inflammatory effects in injured tissue.
  • Combined story: GHK-Cu drives matrix synthesis and antioxidant support; BPC-157 brings the supply lines (blood vessels, growth signals); TB-500 helps the right cells migrate to the right places. Three layers of skin-repair biology.

This is biological logic, not proven synergy in humans. Whether 1+1+1 produces meaningfully better human outcomes than 1+1 or just 1 hasn't been studied.

Commonly studied dosing of components

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision.

Pre-mixed blend products: typical formulations contain GHK-Cu (often 50–100 mg per vial), BPC-157 (5–10 mg per vial), and TB-500 (5–10 mg per vial). Daily-dosing protocols compromise between the components' different individual half-lives.

Separate-dose research-community protocols: some users prefer topical GHK-Cu (cosmetic concentrations, daily application) plus injectable BPC-157 + TB-500 separately at their individual frequencies. This may better match each component's evidence base.

Treatment duration: typical research-community cycle ranges are 4 to 8 weeks. Long-term continuous use of the blend has not been characterized for safety.

Side effects and safety considerations

Reported in research-community use of the components individually or as a blend:

  • Mild injection-site redness or tenderness
  • Mild flushing or warmth shortly after dose
  • Mild nausea (occasional)
  • Mild headache (uncommon)

Theoretical considerations: people with Wilson's disease or copper-metabolism disorders should avoid copper-containing peptides. Any peptide that promotes angiogenesis carries theoretical concerns about effects on tumor biology, there are no reports of GLOW components promoting tumor growth, but the question hasn't been adequately studied. Long-term safety in healthy adults using continuous blends is not characterized.

References

  1. PubMed search of "GHK-Cu + BPC-157 + TB-500" or related combinations: no published human clinical trials of this specific three-peptide combination identified as of May 2026. PubMed
  2. Pickart L. (2008). "The human tripeptide GHK and tissue remodeling." J Biomater Sci Polym Ed, 19(8), 969–988. PubMed
  3. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. (2012). "Thymosin β4: a multi-functional regenerative peptide." Expert Opin Biol Ther, 12(1), 37–51. PubMed
  4. Sikiric P, Seiwerth S, Grabarevic Z, et al. (2018). "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal healing." Curr Pharm Des, 24(18), 1990–2001. PubMed
  5. Maquart FX, Bellon G, Chaqour B, et al. (1993). "In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex GHK-Cu." J Clin Invest, 92(5), 2368–2376. PubMed
For educational and research purposes only. This is not medical advice. The GLOW blend is not FDA-approved as a combined formulation. There are no published human clinical trials of this combination. Two of the three components (BPC-157, TB-500) are on the FDA's Category 2 list. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.